【摘要】 目的　研究肿瘤患者深部真菌感染早期诊断的临床特征及耐药性。方法　根据原发肿瘤治疗过程中的临床表现及实验室检验为依据选择真菌感染患者 ,采用微量稀释法测试药敏试验。结果　发现 5 2例真菌感染者 ,药敏试验结果显示酮康唑耐药率较低为 2 .5 %外 ,依次为两性霉素B 9.6 %、氟康唑 17.3%、伊曲康唑 19.2 %、咪康唑 2 8.8%。结论　筛选出的 5 2例真菌感染患者结合药敏试验合理用药 ,有效率可达 88.5 % ,而耐药性的出现可能与大量使用咪唑类药如氟康唑有关更多还原

【Abstract】 OBJECTIVE To study the early clinical manifestation and the resistance to anti-fungal drugs in deep fungal infection of tumor patients. METHODS The patients with candidiasis were chosen according to the clinical manifestation and laboratory examination in the treatments of tumor. In vitro anti-fungal susceptibility of yeasts was tested. RESULTS A total of 52 cases of candidiasis were found. From them in vitro anti-fungal susceptibility showed that 2.5% were resistant to ketoconazole and 9.6%,17.3%,19.2% and 28.8% were resistant to amphotericin B, fluconazole, itraconazole and miconazole, respectively. CONCLUSIONS The cure rate of 52 cases with fungal infection had reached 88.5%. In vitro testing of the susceptibility of yeasts to anti-fungal agents will play an important role in the appropriate selection of anti-fungal agents for the treatment of fungal infections.The data showed that the wide uses of imidazoles (such as fluconazole) appeared to be associated with emerging resistance to these important anti-fungal agents.更多还原